News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
FCA sets AI governance rules for UK financial firms
The UK Financial Conduct Authority has published expectations on how banks and insurers should govern AI systems. Firms must document risk controls and audit decisions before deployment.
Rocket Lab to buy Iridium satellite operator in $US800M deal
Rocket Lab announced plans to acquire Iridium Communications for $800 million, combining launch services with a deployed constellation of 66 satellites in orbit. The all-cash deal aims to create a vertically integrated space business.
FDA approves Lumvoa for thyroid eye disease in active and chronic forms
Viridian Therapeutics wins first FDA approval for Lumvoa, the first TED treatment with labeling for both active and chronic disease. Clinical data showed proptosis reduction in three weeks.
UAE trial uses 900K genomes to find Alzheimer's risk before symptoms
IROS and M42 launched a genomics-driven clinical trial targeting asymptomatic APOE4 carriers using the Emirati Genome Programme. Here's why population-scale genetic screening matters for prevention.
Lilly's pirtobrutinib wins EU backing for chronic lymphocytic leukaemia
EMA committee recommended Jaypirca for CLL across all treatment lines, with European Commission decision expected in one to two months. US FDA ruling anticipated in H2 2026.
FDA Clears NASP Safety and Efficacy But Halts Approval on Manufacturing
Sobi's gout therapy passed clinical review but faces manufacturing deficiency questions. The FDA wants detail on biological component controls and contract facility operations before resubmission.
Biogen cuts Apellis pipeline, suspends two rare disease trials post-$5.6B buyout
Three months after acquiring Apellis for $5.6 billion, Biogen is pausing or ending most legacy research programs and trimming R&D staff. The move signals a focus on commercializing pegcetacoplan's approved indications.
VIB's 40 spinoffs raised €2B while EU grants fund only 2% of proposals
Belgium's biotech institute fuels startups amid a European funding crisis. VIB has spun out companies like Orionis (Novartis deal: $1.4B) and Rainbow Crops (Gates grant: $7M), but its director warns only 2% of grant submissions succeed across Europe.
SK Biopharm, Insilico Strike $2.5B AI Drug Deal for Brain Disorders
South Korean pharma giant SK partners with AI drug discovery firm Insilico to develop neuroimmune therapies. SK handles late-stage trials and U.S. sales; Insilico handles AI-powered design and early development.
Tecan Adds AI Agents to Lab Platform to Prevent Equipment Failures
Tecan's Introspect platform now runs AI agents powered by NVIDIA's BioNeMo toolkit to spot lab bottlenecks before they disrupt experiments. Early access available for pharma and biotech labs.
India cuts medical device licensing timelines by 25 days
The health ministry proposed faster approvals for Class B, C, and D devices. Class B timelines drop from 140 to 115 days; high-risk devices from 105 to 90 days.
India's nutraceutical market to nearly double to $57B by 2030
India's $30B nutraceutical sector is projected to reach $57B by 2030, growing at 10.5% annually as consumers shift toward preventive health. Here's what's driving the expansion.